Article
Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers
26 Jun 2017
Abstract excerpt
Myocyte Enhancer Factor 2 (MEF2) mediates cardiac remodelling in heart failure (HF) and is also a target of β-adrenergic signalling, a front-line treatment for HF. We identified global gene transcription networks involved in HF with and without β-blocker treatment. Experimental HF by transverse aortic constriction (TAC) in a MEF2 "sensor" mouse model (6 weeks) was followed by four weeks of β-blockade with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
